May 8, 2009

Isis is a Top Pickantisense research

Zacks has selected Isis Pharmaceuticals as their top mid cap pick in biotech with a $22 price target. Future growth will be driven by their antisense research, while the company may presently reap the benefits of their 1,500 patents and partnership programs.

You can read more coverage on ISIS here.

No comments: